GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature.
Bellone. J J; Ghizzoni. L L; Aimaretti. G G; Volta. C C; Boghen. M F MF; Bernasconi. S S; Ghigo. E E
Key Findings
- Oral GHRP‑6 (300 µg/kg) raised GH to ~19 µg/L at 60 minutes, a ~17‑fold increase over baseline.
- The GH response (peak and total exposure) was comparable to that from an IV dose of GHRH‑29.
- The study involved 13 pre‑pubertal children with normal short stature and normal IGF‑1 levels.
Practical Outcomes
- Oral GHRP‑6 can stimulate a robust GH surge, suggesting it could be used in adult self‑experiments for GH boosting. However, the data come from a pediatric cohort, so dosing, safety, and long‑term effects in adults remain unknown. Use caution and consider that more research is needed before adopting it as a routine protocol.
Summary
A small study gave kids with short stature a single oral dose of GHRP‑6 and saw a big jump in growth hormone, about the same as a standard IV hormone test. This shows that GHRP‑6 can work when taken by mouth, at least in children.
Abstract
Growth hormone-releasing peptide 6 (GHRP-6) is a synthetic hexapeptide with a potent GH-releasing activity after intravenous, subcutaneous, intranasal and oral administration in man. Previous data showed its activity also in some patients with GH deficiency. The aim of our study was to verify the GH-releasing activity of oral GHRP-6 administration on GH secretion in children with normal short stature. The effect of oral GHRP-6 (300 micrograms/kg) was compared with that of the maximally effective dose of intravenous GH-releasing hormone (GHRH-29, 1 microgram/kg). As the GHRH-induced GH rise in children is potentiated by arginine (ARG), even when administered by oral route at low dose (4 g), we studied also the interaction of oral GHRP-6 and ARG administration. We studied 13 children (nine boys and four girls aged 6.2-10.5 years, pubertal stage I) with normal short stature (height less than -2 SD score; height velocity more than -2 SD score; normal bone age; insulin-like growth factor I > 70 micrograms/l). In a first group of children (N = 7), oral GHRP-6 administration induced a GH response (mean +/- SEM; peak at 60 min vs baseline: 18.8 +/- 3.0 vs 1.1 +/- 0.3 micrograms/l, p < 0.0006; area under curve: 1527.3 +/- 263.9 micrograms l-1 h-1) which was similar to that elicited by GHRH (peak at 45 min vs baseline: 20.8 +/- 4.5 vs 2.2 +/- 0.9 micrograms/l, p < 0.007; area under curve: 1429.4 +/- 248.2 micrograms l-1 h-1).(ABSTRACT TRUNCATED AT 250 WORDS)
Study Information
pubmed
1995
10.1530/eje.0.1330425